I think we're onto something here. A new paradigm needed in what...

I think we're onto something here. A new paradigm
needed in what type of company delivers these therapies,
as big pharma obviously struggling with the fact
these ddRNAi therapies don't tick the 'take this pill each
day for the rest of your life or you die' box, so central
to their business strategy.

So add Gradalis the Max-Merger please.
Big Biopharma getting it sorted. Adapt or die
big pharma.